An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Financial toxicity is pervasive in rural oncology, with 53% reporting unaffordable care, 50% carrying medical debt, and 70% ...

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...

Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last ...

An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...

MMRd showed no meaningful association with pOR, pCR, or RFS, suggesting limited utility for selecting patients for Gem-iDRS ...

Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...

Detalimogene voraplasmid achieved a 54.0% any-time CR in BCG-unresponsive NMIBC with CIS ± high-grade Ta/T1, with 91% of CRs ...

A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...

Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...

CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...